{"filings":[{"id":887957,"accession_number":"0001193125-26-259481","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-06-05T20:00:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Assembly Biosciences shareholders approve equity plan share increases; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 3 to 2018 Stock Incentive Plan approved; shares reserved increased from 1,478,333 to 2,678,333 (increase of 1,200,000).","Amendment No. 2 to Employee Stock Purchase Plan approved; shares reserved increased from 225,000 to 515,000 (increase of 290,000).","All nine director nominees elected: Altig, Cihlar, Consylman, Cook II, Houghton, Johnson-Pratt, Mahony, McHutchison, Okazaki.","Advisory say-on-pay approved (11,293,061 for, 5,401 against); ratification of Ernst & Young as auditor approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":667676,"accession_number":"0001193125-26-239277","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-05-26T20:10:16+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Assembly Biosciences raises $115M gross in underwritten equity offering; underwriters exercise option in full","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 3,924,624 common shares at $26.50 and pre-funded warrants for 415,000 shares at $26.499.","Net proceeds of approximately $107.4M after underwriting discounts and estimated expenses.","Investors include Gilead Sciences, Commodore Capital, Farallon Capital, and others.","Proceeds to fund clinical development of pipeline candidates and for general corporate purposes.","Underwriters' 30-day option for 566,040 additional shares exercised in full on May 22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":591276,"accession_number":"0001193125-26-235469","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-05-22T11:15:16+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Assembly Biosciences expands ABI-6250 into PBC and PSC; Phase 2 basket study planned Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-6250, oral NTCP inhibitor, to be studied in PBC and PSC basket Phase 2 starting Q1 2027.","Phase 1a completed; data show dose-dependent bile acid elevations confirming target engagement.","Chronic tox studies support longer-term dosing; Phase 2 in HDV remains on track for Q4 2026.","Pre-IND FDA meeting constructive; company views feedback as helpful for advancement.","PSC has no approved therapies; PBC has significant unmet need despite existing treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92796,"accession_number":"0001193125-26-211922","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.","Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.","Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.","Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.","Cash runway projected into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":8213000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103929,"accession_number":"0001193125-26-131872","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Assembly Biosciences adopts 2026 bonus plan; raises CEO bonus target to 65%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved 2026 Corporate Bonus Plan effective Jan 1, 2026 with corporate and individual performance objectives.","CEO Jason Okazaki's bonus target increased from 60% to 65% of base salary via Amendment No. 1 to employment agreement.","Bonus targets range: CEO up to 75%, other executives 30-55%, non-executives up to 28% of base salary.","Bonuses range from 0 to 1.5 times target; payment expected in Q1 of following year, no later than March 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103928,"accession_number":"0001193125-26-115980","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).","Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.","Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.","Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.","Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120200,"accession_number":"0001193125-25-311251","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).","ABI-1179: >99% reduction in high viral load shedding, a transmission surrogate.","ABI-5366 monthly dose: 76% HSV-2 shedding reduction (p<0.01), 88% lesion reduction (p=0.01), 81% high viral load reduction.","ABI-5366 weekly 350 mg confirmed: 94% shedding, 97% lesion reduction vs placebo.","Both candidates well-tolerated; Phase 2 planning for ABI-1179 and ABI-5366 weekly; monthly optimization ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120199,"accession_number":"0001193125-25-274235","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.","Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.","Raised $175M gross proceeds from equity financing with institutional investors in August 2025.","Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.","Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":29834000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136776,"accession_number":"0001193125-25-178092","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Assembly Bio prices $175M equity financing; net proceeds ~$167M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering: 5.6M shares + 1.04M pre-funded warrants at $19.60/unit; net ~$122M.","Gilead purchases 2.3M shares + warrants in private placement at same price; net ~$45M.","Class A warrants exercisable at $21.60, expire 5 years from issuance or 30 days after Phase 2 enrollment announcement.","Class B warrants exercisable after Nov 15, 2026 until Dec 31, 2026; terminate early if $75M non-dilutive collaboration capital received.","Proceeds for general corporate purposes; closings on August 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136775,"accession_number":"0001193125-25-176138","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.","98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.","ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.","PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.","Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136774,"accession_number":"0000950170-25-104020","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.","Cash $75.0M as of June 30, 2025, projected to fund operations into mid-2026.","ABI-6250 Phase 1a interim: mean half-life ~4 days supports once-daily oral dosing; dose-dependent bile acid elevations show NTCP target engagement.","Safety: all AEs grade 1-2; one grade 2 ALT elevation at highest single dose (25 mg), self-limited, no serious AEs.","Phase 1b herpes data (ABI-5366, ABI-1179) on track for fall 2025; positive Phase 1b data for ABI-4334 (HBV) reported earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":19045000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153998,"accession_number":"0000950170-25-089949","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).","Favorable safety: no serious AEs or discontinuations; two grade 3 lab abnormalities resolved with continued dosing.","Half-life supports once-daily oral dosing; exposure at both doses achieved double-digit multiples over target EC50.","Data triggers Gilead's right to opt-in for exclusive license after review of option data package.","ABI-4334 shows potential to inhibit viral replication at 150 mg and cccDNA formation at higher doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153997,"accession_number":"0000950170-25-083830","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Assembly Biosciences appoints new CFO; shareholders approve stock plan share increases","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeanette M. Bjorkquist appointed principal financial officer effective June 5, 2025; Jason A. Okazaki remains CEO.","Shareholders approved Amendment No. 1 to 2018 Stock Incentive Plan: shares reserved increased by 375,000 to 1,478,333.","Amendment No. 2 approved: 225,000 additional shares for performance-based vesting retention grants.","ESPP Amendment No. 1 approved: shares reserved increased from 164,500 to 225,000.","All 10 director nominees elected; Ernst & Young ratified as auditor for FY 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153996,"accession_number":"0000950170-25-066946","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences Q1 2025 net loss $8.8M; cash $91M; pipeline data expected in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.8M ($1.17/diluted share) vs $9.1M in Q1 2024; revenue from Gilead collaboration $9.4M (up from $5.8M).","Cash, equivalents and marketable securities $91.0M as of March 31, 2025; projected to fund operations into mid-2026.","R&D expenses $14.9M (up from $11.9M) driven by ABI-6250 and ABI-5366; G&A $4.5M (slight decrease from $4.6M).","Interim Phase 1b data for HSV candidates ABI-5366 and ABI-1179 expected in fall 2025; Phase 1a data for HDV candidate ABI-6250 in Q3 2025.","Phase 1b data for HBV candidate ABI-4334 (400 mg cohort) expected in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":9419000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172637,"accession_number":"0000950170-25-042660","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences FY 2024 net loss narrows to $40.2M; pipeline advancing with multiple data readouts in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.","Cash $112.1M at year-end; projected to fund operations into mid-2026.","Received $20.1M equity investment and $10M accelerated funding from Gilead.","Phase 1b data for ABI-4334 (HBV capsid modulator) showed mean 2.9 log10 IU/mL HBV DNA decline in 150mg cohort.","Interim Phase 1b efficacy data for ABI-5366 and ABI-1179 (genital herpes) expected fall 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172636,"accession_number":"0000950170-25-024134","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Biosciences reports positive interim Phase 1a results for ABI-1179 in recurrent genital herpes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-1179 had a half-life of ~4 days and high exposure across 50mg-300mg doses, supporting once-weekly oral dosing.","ABI-1179 was well-tolerated with no serious adverse events and all treatment-emergent AEs mild and unrelated.","Company plans to move directly into Phase 1b, running concurrently with Phase 1b of ABI-5366.","Interim Phase 1b data for both ABI-1179 and ABI-5366 anticipated in fall 2025.","ABI-1179 contributed by Gilead Sciences under the Assembly Bio-Gilead collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172635,"accession_number":"0000950170-25-001141","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Assembly Biosciences extends sublease through Sep 2029; ROFR on additional space","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease extended to September 30, 2029 for ~20,000 sq ft in South San Francisco.","Monthly base rent ranges from $64,945 (abated Jan 2025) to $74,537 through 2029.","Right of first refusal to sublease additional 6th-floor space from Arsenal Biosciences.","Sublessee may install improvements including walls, offices, and phone rooms at its cost.","Amendment conditioned on master landlord consent; either party may terminate if not obtained within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189647,"accession_number":"0000950170-24-139962","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Biosciences reports interim Phase 1b data for ABI-4334 with 2.9 log10 IU/mL mean HBV DNA reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-4334 was well-tolerated with favorable safety profile; no serious adverse events or discontinuations in either cohort.","In 150 mg dose cohort, mean HBV DNA declined 2.9 log10 IU/mL and mean HBV RNA declined 2.5 log10 U/mL over 28 days.","Half-life supports once-daily oral dosing; Cmin multiples above EC50 for antiviral activity and cccDNA inhibition.","Enrollment ongoing for 400 mg cohort, expected final cohort; data anticipated in first half of 2025.","Gilead Sciences has opt-in rights to further develop and commercialize ABI-4334 after completion of Phase 1b study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189646,"accession_number":"0000950170-24-138242","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead pays $10M upfront payment creditable against future collaboration obligations.","Opt-in fees for ABI-6250 restructured; total aggregate payments unchanged.","Gilead purchases 940,499 shares at $21.37/share, a 35% premium to 30-day VWAP.","Amendment redefines Phase 1b clinical trial and Triggering Clinical Trial for certain programs.","Additional Funding Payment of $10M due within [***] days; use restricted per Section 15.5(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189645,"accession_number":"0000950170-24-136183","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Assembly Biosciences amends bylaws, tightens advance notice for shareholder proposals and director nominations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholder proposals and director nominations for 2025 annual meeting must be received between Jan 29 and Feb 28, 2025.","Advance notice deadline changed to between 120 and 90 days before first anniversary of prior year's annual meeting.","Stockholders soliciting proxies must use proxy card color other than white; white reserved for Board/Company use.","Director nominees must deliver completed background questionnaire and specific written representations to the Secretary.","Stockholders must update and supplement notices to ensure accuracy as of the record date for the applicable meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189644,"accession_number":"0000950170-24-123466","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Assembly Biosciences enters ATM equity offering agreement with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At-the-market facility permits sale of common stock from time to time; Jefferies acts as agent.","Jefferies earns up to 3.0% commission on gross proceeds of shares sold under the agreement.","Sales may occur on Nasdaq, in block trades, or privately; no minimum number of shares required.","Either party may terminate the Sale Agreement at any time upon written notice.","Shares to be issued under existing effective shelf registration statement (333-270760)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189643,"accession_number":"0000950170-24-123355","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.","Cash $95.0M as of Sept 30, 2024, projected to fund operations into Q1 2026.","Positive Phase 1a interim data for ABI-5366 (HSV) supports once-weekly and once-monthly oral dosing; Phase 1b initiated.","Phase 1b trial for ABI-4334 (HBV) ongoing, interim data expected by end of 2024.","ABI-1179 and ABI-6250 on track to enter clinic by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":21163000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206136,"accession_number":"0000950170-24-108629","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Biosciences reports positive interim Phase 1a results for ABI-5366 in recurrent genital herpes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.","Half-life of approximately 20 days supports both once-weekly and once-monthly oral dosing schedules.","Screening for Phase 1b in participants with recurrent genital herpes is now underway.","Interim Phase 1b results are expected in the first half of 2025.","Single doses of ABI-5366 surpassed target plasma concentrations for antiviral efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206135,"accession_number":"0000950170-24-093946","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.","Revenue from Gilead collaboration $8.5M in Q2 2024 (vs. $0 in Q2 2023); R&D expenses $16.3M (up from $12.5M).","Net loss $11.2M ($1.98 per share) vs. $16.9M ($3.88) in Q2 2023; net loss improved on higher revenue.","Phase 1a/b dosing initiated for ABI-5366 (genital herpes) and Phase 1b for ABI-4334 (chronic HBV infection).","Two additional candidates (ABI-1179, ABI-6250) expected to enter clinic by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":14318000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223183,"accession_number":"0001193125-24-163398","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Assembly Bio raises $12.6M via equity sales to Armistice & Gilead; cash runway into Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $12.6M from sale of common stock and warrants to Armistice Capital and Gilead.","Armistice bought 634,500 shares + warrants; Gilead bought 179,500 shares + warrants at $15.46/combined unit.","Warrants exercisable at $17.00/share, expire June 18, 2029; proceeds for general corporate purposes.","Cash runway extended into Q1 2026; key data readouts: ABI-5366 Phase 1a in Q3 2024, Phase 1b in H1 2025.","Agreement amendments with Gilead extend timeline for potential ownership increase up to 29.9%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223182,"accession_number":"0000950170-24-067951","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 220K share increase to stock plan; ESPP amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended 2018 Stock Incentive Plan increases share reserve by 220,000 to 1,103,333 shares.","Second Amended 2018 ESPP increases reserve to 164,500 shares; removes per-offering-period purchase limit.","All 10 director nominees elected with substantial votes; non-binding advisory votes on executive pay and frequency passed.","Ernst & Young ratified as independent auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223181,"accession_number":"0000950170-24-055650","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Bio reports Q1 net loss $9.1M; CTAs cleared for two clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss narrowed to $9.1M ($1.66/sh) from $19.0M ($4.46) YoY; cash $113M funds ops into H2 2025.","CTAs cleared for Phase 1a/1b of ABI-5366 (genital herpes) and Phase 1b of ABI-4334 (HBV); both on track by mid-2024.","Interim data expected: ABI-5366 Ph1a in Q3 2024; ABI-4334 Ph1b by year-end 2024.","Two more candidates (ABI-1179 and ABI-6250) expected to enter clinic by end of 2024.","Revenue from Gilead collaboration $5.8M in Q1 2024 vs $0 prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242672,"accession_number":"0000950170-24-038044","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.","Revenue from collaborations $7.2M in FY 2023 (vs $0 in 2022), primarily from Gilead partnership.","R&D expenses $48.9M (down from $70.0M); net loss $61.2M ($13.38/share) vs $93.1M ($23.08) in 2022.","Phase 1a interim data for HSV drug ABI-5366 expected Q3 2024; Phase 1b data for HBV drug ABI-4334 by end of 2024.","Entered long-term partnership with Gilead and appointed Anuj Gaggar as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242671,"accession_number":"0000950170-24-032162","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Assembly Biosciences appoints Gilead designee to board, adopts 2024 bonus plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert D. Cook II, Gilead's VP of Risk Governance and Audit, appointed to Board as Gilead designee per Oct 15, 2023 Investor Rights Agreement; no compensation.","Compensation Committee approved 2024 Corporate Bonus Plan effective Jan 1 2024 with cash bonuses tied to corporate and individual objectives.","CEO bonus target up to 75% of base salary; other executive participants 30-55%; non-executive participants up to 28%.","Cash bonuses range from 0 to 1.5x target; paid by March 15 following performance year; employment through payment date required.","Weighting: CEO 100% corporate; C-Level/SVP 75/25; VP/Exec Dir/Sr Dir 50/50; below Sr Dir 25/75."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242670,"accession_number":"0000950170-24-014534","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Assembly Biosciences announces 1-for-12 reverse stock split effective Feb 9, 2024 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-12 ratio effective Feb 9, 2024; trading begins split-adjusted Feb 12 under same symbol ASMB.","Shares outstanding reduced from ~65.8M to ~5.5M; fractional shares paid in cash based on Feb 8 closing price.","Primary purpose is to meet Nasdaq minimum bid price requirement for continued listing.","Stockholders approved reverse split range at Jan 31 special meeting; Board selected 1-for-12 ratio on Jan 31.","New CUSIP 045396207; Equiniti Trust Company acts as exchange agent; proportionate adjustments to equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242669,"accession_number":"0000950170-24-010475","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Assembly Biosciences stockholders approve reverse stock split; Board sets ratio at 1-for-12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved a range of 1-for-7 to 1-for-17 reverse stock split; Board selected 1-for-12 ratio.","Approval of share issuance to Gilead Sciences under October 2023 Stock Purchase Agreement (16.2M votes for).","Reverse split expected to be effectuated as soon as practicable after the January 31, 2024 special meeting.","Adjournment proposal approved with 28M votes for, 9.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242668,"accession_number":"0000950170-24-005024","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Assembly Biosciences terminates license agreement with Indiana University for HBV program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On January 11, 2024, Assembly Biosciences notified IURTC of termination of exclusive license for HBV patents including vebicorvir (VBR).","Termination effective April 11, 2024, 90 days after notice; VBR development was discontinued in July 2022.","Aggregate milestone payments under the license were $0.8 million; royalties ranged from 0.5% to 1.75% on net sales.","Annual diligence maintenance fees of $0.1 million were paid, creditable against milestone payments.","Next-generation capsid assembly modulators (CAMs) were internally discovered and not covered by the terminated license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260058,"accession_number":"0000950170-23-068794","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Assembly Bio appoints Gilead's Cihlar to board and moves HQ to South San Francisco","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Tomas Cihlar, Ph.D., Gilead's SVP of Virology, to the Board effective December 7, 2023, per Investor Rights Agreement.","Dr. Cihlar will not receive compensation for his Board service.","Corporate headquarters relocated to Two Tower Place, 7th Floor, South San Francisco, CA 94080 effective December 1, 2023.","The appointment stems from the October 15, 2023 Investor Rights Agreement with Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260057,"accession_number":"0000950170-23-061105","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.","R&D expenses fell to $10.8M from $18.1M YoY due to trial completions and pipeline discontinuations.","Cash $46.2M at Sep 30; $100M upfront from Gilead in Oct extends cash runway into 2H 2025.","Partnership with Gilead includes opt-in rights on current/future pipeline; Gilead contributed two herpesvirus programs.","Appointed Anuj Gaggar, MD, PhD as CMO; expects four development candidates in clinic by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260056,"accession_number":"0001193125-23-257271","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Assembly Biosciences enters $100M collaboration with Gilead; Gilead gets opt-in rights to pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead pays $85M upfront cash and $15M equity ($1.16/share, 13.1M shares) for collaboration.","Gilead licenses its helicase primase inhibitor and NNPI programs to Assembly.","Gilead has opt-in rights to Assembly programs; exercise fees range from $45M to $125M per program.","Assembly eligible for up to $330M in milestones per program plus royalties (high single to high teens).","Gilead has option to purchase additional shares to own up to 29.9% of Assembly under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277346,"accession_number":"0000950170-23-050808","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Assembly Biosciences receives Nasdaq bid-price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ASMB that bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until March 25, 2024, to regain compliance.","Compliance requires closing bid price ≥$1.00 for ten consecutive business days.","If not cured, may be eligible for second 180-day period with reverse stock split option.","Stock continues trading on Nasdaq Global Select under 'ASMB' with no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277345,"accession_number":"0000950170-23-040590","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.","Cash, cash equivalents and marketable securities $59.8M as of June 30, 2023; projected to fund ops through Q3 2024.","Herpesvirus candidate ABI-5366 entered GLP toxicology; IND/CTA submission planned for H1 2024.","Second development candidate nomination expected in 2023; additional candidate to enter clinic by year-end 2024.","Three abstracts accepted for 2023 International HBV Meeting in Kobe, Japan (Sept 19-23)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277344,"accession_number":"0000950170-23-039043","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Assembly Biosciences subleases ~20K sq ft HQ in South San Francisco for 24 months","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sublease with Arsenal Biosciences for 2 Tower Place, 7th Floor, South San Francisco; term begins Nov 1, 2023 or later.","Monthly base rent: $109,906.50 for months 1-12; $113,753.23 for months 13-24.","Security deposit of $219,813 required; Company pays share of operating expenses, taxes, utilities.","Option to extend through balance of sublessor's master lease; rent capped at $6.25/sq ft with 3.5% annual increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295241,"accession_number":"0000950170-23-024879","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders reject authorized share increase to 225M at ASMB annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with no opposition.","Say-on-pay advisory approved (10.6M for, 1.7M against).","Ratification of Ernst & Young as auditor for FY2023 approved (21.5M for).","Amendment to 2018 Stock Incentive Plan increasing share reserve from 8.6M to 10.6M shares approved.","Proposal to increase authorized common stock from 150M to 225M shares failed, limiting future equity issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295240,"accession_number":"0000950170-23-017924","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.","Cash, cash equivalents and marketable securities $73.0M as of March 31, 2023, projected to fund ops into Q3 2024.","Nominated first herpesvirus candidate ABI-5366; plans to enter clinic first half 2024; expects additional candidate nomination in 2023.","Evaluating partnering options for core HBV inhibitor portfolio to focus on expanded virology programs.","Multiple abstracts accepted for presentation at EASL 2023 in June for HBV/HDV entry inhibitor and core inhibitor data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295239,"accession_number":"0000950170-23-013272","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Bio reports positive Phase 1a data for ABI-4334; to partner core inhibitor portfolio, focus on ABI-5366","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.","Phase 1a safety: mild-to-moderate AEs, no pattern, no clinically significant ECG abnormalities.","Company will partner core inhibitor portfolio; no further internal clinical development for HBV cure.","Prioritizing ABI-5366 (genital herpes) with Phase 1 expected H1 2024; second candidate by end of 2024.","Cash runway extended into Q3 2024 due to reprioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315808,"accession_number":"0000950170-23-009175","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Assembly Bio prioritizes ABI-4334, pauses ABI-H3733 on chronic toxicology finding; Q4 2022 net loss $93.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.","Phase 1b for ABI-H3733: all 7 HBeAg-negative patients achieved HBV DNA below LLOQ by day 21; chronic toxicology in one species halted program.","Net loss $93.1M ($1.92/share) for FY2022 vs $129.9M ($3.00/share) in 2021; cash $91.6M as of Dec 31, 2022, funding into mid-2024.","Second development candidate nomination expected in 2023; IND/CTA for herpesvirus candidate ABI-5366 planned for first half 2024.","CEO Jason Okazaki appointed as previously reported; no new leadership change in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315807,"accession_number":"0000950170-23-002893","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Biosciences nominates first herpesvirus candidate ABI-5366, a long-acting HSV-2 helicase inhibitor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.","Preclinical data show nanomolar potency in vitro and exceptionally low clearance, supporting at least monthly dosing.","Company plans to file IND/CTA in first half of 2024; more data expected at scientific conferences in 2023.","First development candidate from Assembly Bio's expanded focus beyond hepatitis B.","Current therapies for high-recurrence genital herpes are only partially effective; helicase inhibitors previously showed greater reductions in shedding and lesions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434662840.5784672,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334140,"accession_number":"0000950170-22-026736","cik":1426800,"company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA